Stay updated with breaking news from Adjuvant. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Approval based on Phase 3 CheckMate -274 trial results showing that adjuvant treatment with Opdivo significantly reduced patients' risk of disease recurrence or death compared to placebo Opdivo
KENILWORTH (NJ) (dpa-AFX) - The European Commission has approved Merck & Co., Inc.'s (MRK) anti-PD-1 therapy, KEYTRUDA, as monotherapy for the adjuvant treatment of adults with renal cell carcinoma
KEYTRUDA Is Now Approved as Monotherapy for Adults With RCC at Increased Risk of Recurrence Following Nephrectomy, or Following Nephrectomy and Resection of Metastatic Lesions KEYTRUDA Is the First
Targeted therapy (BRAF inhibitor plus MEK inhibitor) is now among the possible treatment options for patients with BRAF mutation-positive stage III or stage IV melanoma. This makes prompt BRAF mutation testing an important step in the management of patients diagnosed with stage III or IV melanoma; one that can help better ensure that the optimal choice of systemic treatment is initiated with minimal delay. This article offers guidance about when and how BRAF mutation testing should be conducted when patients are diagnosed with melanoma in Australia. Notably, it recommends that pathologists ref...
Scientists at the La Jolla Institute for Immunology and MIT have invented a promising new nanoparticle that significantly improves vaccine responses in animal studies.